Literature DB >> 17453948

Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.

Kandalam Mallikarjuna1, Vaijayanthi Pushparaj, Jyotirmay Biswas, Subramanian Krishnakumar.   

Abstract

The immunoreactivity of epidermal growth factor receptor (EGFR) ezrin, hepatocyte growth factor receptor (HGF), and c-Met was studied in 60 uveal melanomas and was correlated with clinicopathologic parameters. Metastases were diagnosed in the patients with uveal melanoma between 5 years and 8 years (median, 6.5 years) after enucleation. Using Kaplan-Meier statistical analysis, we found a significant association between high c-Met expression and death due to uveal melanoma (p < 0.03). EGFR was expressed in 18 of 60 (30%) tumors; ezrin was expressed in 30 of 60 (50%) tumors. Tumors with liver metastasis (n = 6) showed higher expression of c-Met (p = 0.0009) compared with the tumors with no extension/extrascleral extension without liver metastasis (groups A-45 and B-9). HGF was negative in all the six tumors that had liver metastasis. Further studies are required to understand the possible mechanism of ligand-independent c-Met activation in patients with uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453948     DOI: 10.1080/02713680601161220

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  27 in total

1.  Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).

Authors:  Jason J Luke; Daniel J Olson; Jacob B Allred; Carrie A Strand; Riyue Bao; Yuanyuan Zha; Timothy Carll; Brian W Labadie; Bruno R Bastos; Marcus O Butler; David Hogg; Pamela N Munster; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

2.  Identify the signature genes for diagnose of uveal melanoma by weight gene co-expression network analysis.

Authors:  Kai Shi; Zhi-Tong Bing; Gui-Qun Cao; Ling Guo; Ya-Na Cao; Hai-Ou Jiang; Mei-Xia Zhang
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

Review 3.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

Review 4.  Emerging roles of microRNAs and their implications in uveal melanoma.

Authors:  Chun Yang; Yuejiao Wang; Pierre Hardy
Journal:  Cell Mol Life Sci       Date:  2020-08-11       Impact factor: 9.261

Review 5.  Metastatic uveal melanoma: biology and emerging treatments.

Authors:  Scott E Woodman
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

6.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

7.  First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

Authors:  Aiwu Ruth He; Roger B Cohen; Crystal S Denlinger; Ashwin Sama; Ariel Birnbaum; Jimmy Hwang; Takami Sato; Nancy Lewis; Michelle Mynderse; Michele Niland; Jennifer Giles; Johan Wallin; Brian Moser; Wei Zhang; Richard Walgren; Elizabeth R Plimack
Journal:  Oncologist       Date:  2019-03-04

Review 8.  The biology and management of uveal melanoma.

Authors:  Takami Sato; Fei Han; Akira Yamamoto
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

9.  Uveal melanoma: Ocular and systemic disease.

Authors:  Cristina Miyamoto; Matthew Balazsi; Silvin Bakalian; Bruno F Fernandes; Miguel N Burnier
Journal:  Saudi J Ophthalmol       Date:  2012-04

Review 10.  Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.

Authors:  M Mimeault; S K Batra
Journal:  Panminerva Med       Date:  2008-03       Impact factor: 5.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.